Breaking News, Financial News

Financial Report: Baxter 4Q09

Late-stage programs increase R&D costs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter 4Q09 4Q Revenues: $3.4 billion (+11%) 4Q Earnings: $576 million (+1%) FY Revenues: $12.6 billion (+2%) FY Earnings: $2.2 billion (+9%) Comments: Baxter took a $56 million charge in 4Q09 for restructuring costs. The BioScience business rose 12% in 4Q09 to $1.5 billion, aided by foreign currency fluctuations. Medication Delivery sales rose 12% to $1.3 billion in the quarter. Renal evens were up 12% to $625 million. For FY09, BioScience was up 5% to $5.6 billion, Medication De...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters